856767-09-4

Basic information

• Product Name: 4-broMo-2-fluoro-6-Methoxybenzaldehyde
• Synonyms: 4-broMo-2-fluoro-6-Methoxybenzaldehyde;Benzaldehyde, 4-broMo-2-fluoro-6-Methoxy-
• CAS NO: 856767-09-4
• Molecular Formula: C8H6BrFO2
• Molecular Weight: 233.0344432
• Mol File: 856767-09-4.mol

Chemical Properties

• Boiling Point: 270.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.601±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-broMo-2-fluoro-6-Methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-fluoro-6-Methoxybenzaldehyde(856767-09-4)
• EPA Substance Registry System: 4-broMo-2-fluoro-6-Methoxybenzaldehyde(856767-09-4)

Safety Data

• Hazardous Substances Data: 856767-09-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-fluoro-6-methoxybenzaldehyde is used as a key intermediate in the synthesis of dihydropyrimidines, which are a class of compounds with significant biological activity. These dihydropyrimidines have been identified as Brd9 bifunctional degraders, which are important for the treatment and prophylaxis of Brd9-mediated diseases.

Upstream product

• 29578-39-0 1-bromo-3-fluoro-5-methoxybenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 457051-15-9 4-bromo-2-fluoro-6-methoxy-benzonitrile 
• 67-56-1 methanol 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 124-41-4 sodium methylate 
• 461-96-1 3,5-difluorobromobenzene 
• 74-88-4 methyl iodide 
• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 

Downstream Products

• 885519-21-1 6-bromo-4-methoxy-1H-indazole 
• 885521-13-1 methyl 4-methoxy-1H-indazole-6-carboxylate 
• 1245215-47-7 methyl 4-methoxy-2-methyl-2H-indazole-6-carboxylate 
• 1245215-48-8 methyl 4-hydroxy-2-methyl-2H-indazole-6-carboxylate 

Relevant articles and documents

Aryl imidazole derivative and application thereof

The invention relates to an aryl imidazole derivative and application thereof. The aryl imidazole derivative is a compound shown as a formula (I) in the description or pharmaceutically acceptable salt thereof. The invention also discloses application of the aryl imidazole derivative in preparation of drugs for treating cancers. The invention further discloses application of the aryl imidazole derivative in preparation of drugs for treating diseases caused by EGFR mutation.

Tricyclic Indazoles - A Novel Class of Selective Estrogen Receptor Degrader Antagonists

Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.

METHODS AND COMPOUNDS FOR TREATING DISORDERS

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY

The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.

PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH, wherein R2 is selected from the group consisting of -C1-3-alkyl, -C1-3-haloalkyl, F, Br, CI, wherein Y is selected from -O- or -CH2-, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

INDAZOLE DERIVATIVES THAT DOWN-REGULATE THE ESTROGEN RECEPTOR AND POSSESS ANTI-CANCER ACTIVITY

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

CHEMICAL COMPOUNDS

The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.